Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors
- PMID: 12384518
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors
Abstract
Disruption of the TSC1 or TSC2 gene leads to the development of tumors in multiple organs, most commonly affecting the kidney, brain, lung, and heart. Recent genetic and biochemical studies have identified a role for the tuberous sclerosis gene products in phosphoinositide 3-kinase signaling. On growth factor stimulation, tuberin, the TSC2 protein, is phosphorylated by Akt, thereby releasing its inhibitory effects on p70S6K. Here we demonstrate that primary tumors from tuberous sclerosis complex (TSC) patients and the Eker rat model of TSC expressed elevated levels of phosphorylated mammalian target of rapamycin (mTOR) and its effectors: p70S6K, S6 ribosomal protein, 4E-BP1, and eIF4G. In the Eker rat, short-term inhibition of mTOR by rapamycin was associated with a significant tumor response, including induction of apoptosis and reduction in cell proliferation. Surprisingly, these changes were not accompanied by significant alteration in cyclin D1 and p27 levels. Our data provide in vivo evidence that the mTOR pathway is aberrantly activated in TSC renal pathology and that treatment with rapamycin appears effective in the preclinical setting.
Similar articles
-
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.Genes Chromosomes Cancer. 2005 Mar;42(3):213-27. doi: 10.1002/gcc.20118. Genes Chromosomes Cancer. 2005. PMID: 15578690
-
Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.Pediatr Res. 2005 Jan;57(1):67-75. doi: 10.1203/01.PDR.0000147727.78571.07. Epub 2004 Nov 19. Pediatr Res. 2005. PMID: 15557109
-
Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis.Oncogene. 2004 Apr 22;23(19):3495-500. doi: 10.1038/sj.onc.1207468. Oncogene. 2004. PMID: 14990989
-
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.Oncogene. 2005 Nov 14;24(50):7475-81. doi: 10.1038/sj.onc.1209090. Oncogene. 2005. PMID: 16288294 Review.
-
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. doi: 10.1093/hmg/ddi260. Hum Mol Genet. 2005. PMID: 16244323 Review.
Cited by
-
Carbonic Anhydrase 2 Deletion Delays the Growth of Kidney Cysts Whereas Foxi1 Deletion Completely Abrogates Cystogenesis in TSC.Int J Mol Sci. 2024 Apr 27;25(9):4772. doi: 10.3390/ijms25094772. Int J Mol Sci. 2024. PMID: 38731991 Free PMC article.
-
Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation.Pharmaceuticals (Basel). 2024 Apr 19;17(4):527. doi: 10.3390/ph17040527. Pharmaceuticals (Basel). 2024. PMID: 38675487 Free PMC article.
-
Rapamycin and rapalogs for tuberous sclerosis complex.Cochrane Database Syst Rev. 2023 Jul 11;7(7):CD011272. doi: 10.1002/14651858.CD011272.pub3. Cochrane Database Syst Rev. 2023. PMID: 37432030 Free PMC article. Review.
-
Induction by rapamycin and proliferation‑promoting activity of Hspb1 in a Tsc2‑deficient cell line.Exp Ther Med. 2023 May 12;26(1):315. doi: 10.3892/etm.2023.12014. eCollection 2023 Jul. Exp Ther Med. 2023. PMID: 37273756 Free PMC article.
-
Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.JCI Insight. 2023 May 8;8(9):e166850. doi: 10.1172/jci.insight.166850. JCI Insight. 2023. PMID: 36927688 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous